Protease-activated receptor 2 (PAR-2) is expressed in various tissues, including lung, and when activated, promotes inflammation, differentiation, and migration of dendritic cells. We found that combining influenza virosomes containing hemagglutinin and neuraminidase with a PAR-2 agonist peptide (PAR-2AP) in an intranasal prime boost approach increased survival of mice challenged weeks later with lethal influenza virus over that by virosome or PAR-2AP prime boost alone. No weight loss occurred from influenza challenge after virosome-plus-PAR-2AP prime boost compared with either virosomes or PAR-2AP alone. Thus, virosomes plus PAR-2AP prevented morbidity as well as mortality. I nfluenza viruses are a common cause of acute human respiratory infections and can result in high morbidity and mortality (1-3). Infections by seasonal or pandemic influenza virus strains are each capable of leading to significant mortality (1-3). For example, the global spread of the pandemic H1N1 2009 virus resulted in over 18,000 deaths (4). Vaccination is an effective and sometimes critical strategy to prevent influenza infections and subsequent disease (5, 6). Efforts are under way to improve vaccine formulations, with the goal to more effectively ensure robust and long-lasting immunity (6-8). This is a particular challenge for the most disease-susceptible populations, such as the very young, the elderly, and the immunocompromised (8, 9).
In addition to exploring the choice of influenza Ag(s) to improve vaccine formulations, efforts are also focusing on identifying the optimal site of vaccination and the discovery of new adjuvants to boost the magnitude and possibly type of immune response elicited by the vaccine (7, 10). Delivery of influenza vaccines to the respiratory mucosa is an attractive and relatively simple approach, with accessibility through the intranasal route, and can lead to effective local immune responses as well as systemic immune responses (11, 12) . A potential drawback of mucosal vaccination is that it can result in tolerance (13). This can be overcome using strong adjuvants, with the choice of adjuvant able to affect the intensity and quality of the immune response from mucosal vaccination (14-16). However, the number of mucosal adjuvants are few, and they can be limited in the type of immune stimulation achieved (17) (18) (19) . Increasing and diversifying the repertoire of adjuvants that are effective when delivered at mucosal surfaces and their immune-stimulating capabilities may be beneficial in facilitating improved mucosal vaccines.
Protease-activated receptor 2 (PAR-2) is a member of a family of seven-pass transmembrane receptors that is activated by protease digestion (20) (21) (22) . Enzyme cleavage of the PAR-2 N terminus exposes a tethered ligand that binds to an activation site on an extracellular loop of the parent receptor, resulting in G-protein-coupled signaling (20, 21, 23) . A number of serine proteases, including mast cell tryptase, neutrophil proteinase 3, and activated coagulation factors, can activate PAR-2 (24-27). The need for the initiating protease can be bypassed by the use of synthetic peptides with structural similarity to the tethered ligands, which directly activate PAR-2 (27, 28). PAR-2 has been associated with the development of inflammatory reactions and is expressed in human and mouse airways (13, 29) . Using the PAR-2 agonist peptide (PAR-2AP) SLIGRL-NH 2 , we have shown that activation of PAR-2 in the context of inhalation of a model Ag, OVA, overcomes tolerance and results in allergic sensitization to OVA (13). 
